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Abstract
Background: A number of prognostically relevant clinicopathological variables have been proposed for
pancreatic neuroendocrine neoplasms. However, a standardized prognostication system has yet to be
established for patients undergoing potentially curative tumour resection.
Methods: We examined a prospectively maintained, single-institution database to identify patients who
underwent potentially curative resection of non-metastatic primary pancreatic neuroendocrine neo-
plasms. Patient, operative and pathological characteristics were analysed to identify variables associated
with disease-specific and disease-free survival.
Results: Between 1991 and 2007, 43 patients met inclusion criteria. After a median follow-up of 68
months, 5-year disease-specific survival was 94% and 5-year disease-free survival was 72%. Tumours
sized 5 cm and vascular invasion were associated with worse disease-specific survival. Tumours sized
5 cm, nodal metastases, positive resection margins and perineural invasion were associated with worse
disease-free survival. A scoring system consisting of tumour size 5 cm, histological grade, nodal
metastases and resectionmargin positivity (SGNM) permitted stratification of disease-specific (P = 0.006)
and disease-free (P = 0.0004) survival. This proposed scoring system demonstrated excellent discrimi-
nation of individual disease-specific and disease-free survival outcomes as reflected by concordance
indices of 0.814 and 0.794, respectively.
Conclusions: A simple scoring system utilizing tumour size, histological grade, nodal metastases and
resection margin status can be used to stratify outcomes in patients undergoing resection of primary
pancreatic neuroendocrine neoplasms.
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Introduction
Pancreatic neuroendocrine neoplasms are rare tumours with an
annual incidence of one to five per 100 000.1,2 Perhaps as a result
of increased awareness and improved diagnostic capabilities, their
prevalence has increased substantially over the last 25 years.3
Although usually indolent, the biological behaviour of pancreatic
neuroendocrine neoplasms ranges from benign to frankly malig-
nant. However, classic criteria that define malignant behaviour,
such as local invasion and presence of lymph node or distant
metastases, have not always correlated with risk of recurrence and
death.4
A number of clinical and pathological parameters have been
used to classify these neoplasms for prognostication and to define
criteria for surgical therapy. Incorporation of staging variables
(size, lymph node and distant metastases) and histological vari-
ables (presence of necrosis, secretory function, mitotic index,
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proliferative index, perineural invasion, vascular invasion) have
resulted in accurate, but sometimes complex, classification
schemes.4,5 Most of these have divided pancreatic neuroendocrine
neoplasms into well- and poorly differentiated neoplasms; high-
grade neuroendocrine carcinoma appears to be a separate disease
entity with a poor prognosis regardless of treatment.6
Previous analyses of resected pancreatic neuroendocrine neo-
plasms have included patients with metastatic and locally
advanced tumours, or have excluded patients with hormone-
secreting tumours.4,5,7–10 This heterogeneity is likely to render their
findings less applicable to patients with resectable, localized
disease. In this study, we analysed the individual, operative and
pathological characteristics of patients with non-metastatic
pancreatic neuroendocrine neoplasms undergoing potentially
curative tumour resection. Our aim was to create a simplified,
reproducible prognostication system to stratify this patient popu-
lation according to risk for disease recurrence and death.
Materials and methods
Patients who underwent potentially curative resection of primary
pancreatic neuroendocrine neoplasms at the University of Wis-
consin School of Medicine and Public Health were identified from
a prospectively maintained database after institutional review
board approval. Potentially curative resection was defined as sur-
gical removal of all macroscopic disease (R0 or R1 resection);
patients undergoing repeat tumour resections and those with evi-
dence of distant metastatic disease and/or locally advanced unre-
sectable disease were excluded from analysis. Tumour location was
determined preoperatively with computed tomography, magnetic
resonance imaging and somatostatin receptor scintigraphy as
deemed necessary by the treating physicians. Additional therapeu-
tic modalities including chemotherapy and somatostatin analogue
therapy were used at the discretion of treating physicians. Demo-
graphic and operative data were collected, and all pathological
specimens were re-examined by a single pathologist (AGL) to
confirm the diagnosis of pancreatic neuroendocrine neoplasm
and to analyse histological characteristics. These included tumour
size, location, perineural and vascular invasion, mitotic rate,
necrosis, status of surgical margin and lymph node metastases.
The lymph node ratio (LNR), defined as the ratio of malignant to
total lymph nodes resected, was calculated for each patient. Neo-
plasms were classified as low grade (2 mitoses per 50 high-
power fields and no necrosis) or intermediate grade (>2 mitoses
per 50 high-power fields and/or focal necrosis) according to pre-
viously defined criteria.4 Patients were followed clinically and with
tumour markers and cross-sectional imaging as deemed neces-
sary.Medical record review and patient contact were performed to
obtain information on survival and disease status. Disease recur-
rence was defined by radiographic evidence of new tumours.
Overall survival (OS), disease-specific survival (DSS) and disease-
free survival (DFS) were calculated using the Kaplan–Meier
method. Univariate analysis was performed with the log-rank test
for categorical variables and with Cox regression analysis for con-
tinuous variables. Statistical significance was defined as P < 0.05.
All variables found to have P < 0.1 by univariate analysis for either
DSS or DFS were combined into potential three- or four-variable
scoring systems in which one point was assigned for the presence
of each potentially prognostic variable. Depending on the pres-
ence of each variable, scores lay in the range of 0–3 for three-
variable systems and 0–4 for four-variable systems. The
association between each possible scoring system combination
and DSS and DFS was evaluated using the log-rank test. The
predictive ability of the optimal prognostic scoring system to dis-
criminate DSS and DFS outcomes was quantified using the
Harrell’s concordance index (c-index).11 The c-index is calculated
as the probability that, for each randomly generated pair of
patients from a dataset, the patient with the favourable prognostic
score survived longer than the patient with the unfavourable
prognostic score. A prognostication system with a c-index of 1
indicates that the prognostic system predicted the correct
outcome in all cases; a c-index of 0 implies that the incorrect
outcome was predicted in all cases, and a c-index of 0.5 means that
the system correctly predicted the outcome 50% of the time (in
effect, demonstrating no predictive ability). Non-informative
pairs (e.g. pairs for whom survival was equal or in which the
survivor had a shorter follow-up interval) were not included in
the calculation of the c-index.
Results
Patient characteristics
A total of 43 patients underwent potentially curative tumour
resection of non-metastatic pancreatic neuroendocrine neo-
plasms between 1991 and 2007. The majority of patients were
female and most tumours were localized in the pancreatic body
and tail (Table 1).
Perioperative characteristics
Median postoperative length of hospital stay was 7 days (range
3–28 days). The majority of patients underwent formal pancreatic
resections for tumour extirpation. Most patients underwent R0
resections and no perioperative mortalities were encountered
(Table 1).
Histological characteristics
Nineteen low-grade and 24 intermediate-grade neoplasms were
identified in this patient population. Thirty-seven patients had
single tumours and six patients had two or three tumours
resected. The mean size of the largest tumours resected was
43 mm (range 5–170 mm). Vascular, perineural and lymphatic
invasion were seen in four, six and eight patients, respectively.
Eighteen patients had lymph node metastases. The mean number
of lymph nodes resected was seven (range 0–38) (Table 1).
Outcomes
After a median follow-up of 68 months, 5-year OS, DSS and DFS
were 91%, 94% and 72%, respectively (Fig. 1). Median OS, DSS
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and DFS were not reached. Three patients had local or regional
recurrence and four were diagnosed with distant recurrence
during follow-up. Four of these seven patients had undergone R0
resections. Median time to recurrence was 24 months (range 4–96
months) and median survival after recurrence was 49 months.
The onset of disease recurrence was associated with worse overall
survival (P = 0.012).
Prognostic factors
On univariate analysis, variables associated with worse DSS were
size5 cm (P = 0.041) and lymphovascular invasion (P = 0.044).
Multivariate analysis was not undertaken because of the limited
sample size and number of events.Variables associated with worse
DFS on univariate analysis were tumour size 5 cm (P = 0.032),
positive resection margin (P < 0.0001), lymph node metastasis (P
= 0.007) and perineural invasion (P = 0.014) (Tables 2 and 3).
Scoring system
The variables of tumour size 5 cm, intermediate histological
grade, positive margin, nodal metastases, vascular invasion and
perineural invasion were analysed as three- or four-variable
scoring systems. A scoring system giving one point each for
tumour size 5 cm, intermediate histological grade, presence of
lymph node metastases and resection margin positivity (SGNM)
was found to have the strongest association with DSS and DFS. To
permit optimal discrimination of outcomes, this scoring system
Table 1 Summary of demographic, histological and operative char-
acteristics of 43 patients undergoing potentially curative resection of
localized primary pancreatic neuroendocrine neoplasms
Variable Mean  SD (% or range)
Age, years 53.4  15.6 (24–81)
Female 29 (67%)
Operation
Pancreaticoduodenectomy 15 (35%)
Distal pancreatectomy 23 (53%)
Enucleation 5 (12%)
Maximal tumour size, cm 4.3  3.3 (0.5–17.0)
Tumour number 1.2  0.4 (1–3)
Multifocal disease 6 (14%)
Microscopic margin positivity 7 (18%)
Nodal metastases 18 (42%)
Number of nodes resected 7.2  7.7 (0–38)
Number of positive nodes 1.1  2.4 (0–11)
Lymph node ratio 0.14  0.24 (0–1)
Vascular invasion 4 (10%)
Perineural invasion 6 (14%)
Grade
Low 19 (44%)
Intermediate 24 (56%)
60-day mortality 0 (0%)
Length of stay, days 8.4  4.5 (3–28)
Median length of stay, days 7
Median follow-up of survivors, months 68
SD, standard deviation
Figure 1 Kaplan–Meier estimates of survival in 43 patients under-
going potentially curative resection of primary pancreatic neuroen-
docrine neoplasms. (A) Disease-specific survival (n = 43); (B)
disease-free survival (n = 43)
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was used to divide patients into two groups (with scores of 0–1
and 2–4) for stratification of DSS outcomes and into four groups
(with scores of 0, 1, 2 and3) for stratification of DFS outcomes.
Increasing SGNM score correlated with DSS (P = 0.006) and DFS
(P = 0.0004). The c-index of the DSS scoring system was 0.814
(95% confidence interval [CI] 0.727–0.902); the c-index of the
DFS scoring system was 0.797 (95% CI 0.677–0.911) (Tables 2–5;
Figs 2 and 3).
Discussion
Optimal treatment guidelines for pancreatic neuroendocrine neo-
plasms are obfuscated by their relative rarity and indolence. It is
Table 2 Demographic, histological and operative variables associated with disease-specific survival in 43 patients undergoing potentially
curative resection of localized primary pancreatic neuroendocrine neoplasms
Variable Number of patients Median DSS, months P-value (univariate) Median DFS, months P-value (univariate)
Gender
Male 14 NR 97
Female 29 NR 0.457 NR 0.487
Age
<50 years 16 NR NR
50 years 27 NR 0.896 97 0.400
Grade
Low 19 NR NR
Intermediate 24 NR 0.244 97 0.091
Tumour size
<5 cm 29 NR NR
5 cm 14 106 0.041 97 0.032
Tumour multifocality
Absent 37 NR NR
Present 6 86 0.724 97 0.318
Margin
Negative 36 NR NR
Positive 7 106 0.074 25 <0.001
Nodal status
Negative 25 NR NR
Positive 18 NR 0.486 46 0.007
Vascular invasion
Absent 39 NR NR
Present 4 NR 0.038 38 0.349
Perineural invasion
Absent 37 NR NR
Present 6 NR 0.422 25 0.014
Statistically significant values are shown in bold
DFS, disease-free survival; DSS, disease-specific survival; NR, not reached
Table 3 Disease-specific and disease-free survival in 43 patients
with resected pancreatic neuroendocrine neoplasms
SGNM score n 5-year DSS, % 5-year DFS, %
0 8 100 100
1 17 100 86
2 11 89 60
3 4 89 25
4 3 67 33
SGNM, tumour size, grade, lymph node status, resection margin status;
DFS, disease-free survival; DSS, disease-specific survival
Table 4 Disease-specific survival based on SGNM score in 43
patients undergoing potentially curative resection of primary pan-
creatic neuroendocrine neoplasms
SGNM score n 5-year DSS, % P-value
0–1 25 100 0.006
2–4 18 86
Statistically significant values are shown in bold
SGNM, tumour size, grade, lymph node status, resection margin status;
DSS, disease-specific survival
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evident that patients with localized neoplasms are more likely to
undergo attempted resection and have significantly better prog-
noses than patients with locally advanced or metastatic neo-
plasms.12,13 Most studies that have attempted to define prognostic
criteria for pancreatic neuroendocrine neoplasms have included
patients with localized and metastatic neoplasms; as a result, their
findings may have limited applicability for patients with localized
disease.4,5,13–15 The World Health Organization system divides
pancreatic neuroendocrine neoplasms into well-differentiated
neuroendocrine tumours, well-differentiated neuroendocrine
tumours of uncertain behaviour, well-differentiated pancreatic
neuroendocrine carcinomas and poorly differentiated neuroen-
docrine carcinomas.16,17 This system incorporates the presence of
metastases, gross invasion, tumour diameter, angio-invasion,
mitoses and proliferative index. It has been criticized for being
based more on expert opinion than on published data,5 and has
limited utility for the subset of patients undergoing complete
gross resection of pancreatic tumours. Bilimoria et al.12 used the
National Cancer Database to validate the American Joint Com-
mittee on Cancer (AJCC) classification system for pancreatic
adenocarcinomas for prognostication of pancreatic neuroendo-
crine neoplasms. They reported that tumour size and the presence
of lymph node and distant metastases can be used to reliably
stratify operatively managed and non-operatively managed pan-
creatic neuroendocrine patients according to 5- and 10-year sur-
vival.12 Similarly, the European Neuroendocrine Tumour Society
and Rindi et al. examined the use of the tumor node metastasis
(TNM) system for all gastroenteropancreatic neuroendocrine
tumours.8,18 In the present study, we focused on patients under-
going resection of localized pancreatic neuroendocrine neoplasms
and determined that tumour size, histological grade, lymph node
metastases and resection margin status can be combined in a
simplified prognostication system (SGNM) that correlates with
risk for disease recurrence (P = 0.0004) and death (P = 0.0006).
This scoring system demonstrates a strong predictive ability to
discriminate DSS and DFS outcomes as measured by its c-indices
of 0.797 and 0.814, respectively. These quantitative measures of
predictive ability compare very favourably with c-indices that have
been calculated for novel prognostic nomograms developed to
predict individual outcomes for patients with pancreatic adeno-
Table 5 Disease-free survival based on SGNM score in 43 patients
undergoing potentially curative resection of primary pancreatic neu-
roendocrine neoplasms
SGNM score n 5-year DFS, % P-value
0 18 100 0.004
1 17 86
2 11 60
3–4 7 14
Statistically significant values are shown in bold
SGNM, tumour size, grade, lymph node status, resection margin status;
DFS, disease-free survival
Figure 2 Disease-specific survival according to SGNM score in 43
patients undergoing potentially curative resection of primary pan-
creatic neuroendocrine neoplasms (P = 0.006). SGNM, size, grade,
lymph node status, resection margin status
Figure 3 Disease-free survival according to SGNM score in 43
patients undergoing potentially curative resection of primary pan-
creatic neuroendocrine neoplasms (P = 0.004). SGNM, size, grade,
lymph node status, resection margin status
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carcinoma (0.64),19 hepatocellular carcinoma (0.74),20 extremity
sarcoma (0.77)21 and gastric adenocarcinoma (0.80).22
This SGNM scoring system is more effective in discriminating
differential outcomes for disease recurrence than for disease-
related mortality. This probably reflects the paucity of patients
who died over the course of follow-up in our study. Indeed, after
a median follow-up of 68 months, 5-year OS and DSS rates were
91% and 94%, respectively. By contrast, our own recent analysis of
patients undergoing resection of hepatic neuroendocrine
metastases identified a 5-year OS of 65%.23 In previous studies
that have grouped patients with localized and advanced or meta-
static pancreatic neuroendocrine neoplasms together, 5-year sur-
vival has ranged between 49% and 93%.2,4,5,10,14,15,24
We observed that tumour size >5 cm correlated with DSS and
DFS on univariate analysis (P = 0.041 and P = 0.032, respectively).
Other authors have similarly reported that tumour size correlates
with survival on univariate, but not multivariate, analysis.4,5,15
The prognostic relevance of tumour necrosis and mitotic rate
were previously validated by Hochwald et al., who used these his-
tological factors to classify pancreatic neuroendocrine neoplasms
into low and intermediate grades that correlate with survival.4,25
These same criteria have also been shown to be prognostically
important for resected hepatic neuroendocrine neoplasms.23 In
the present study, the association between histological grade
(using these same criteria) and disease recurrence neared but did
not reach statistical significance (P = 0.091). However, inclusion of
histological grade in our proposed classification scheme permit-
ted more accurate prognostication of DSS (P = 0.123 without
grade, P = 0.006 with grade) and better discrimination of differ-
ences in DFS (data not shown). The presence of vascular invasion
and that of perineural invasion were independently associated
with worse DSS and DFS, respectively; however, inclusion of these
pathological parameters did not improve the ability of the scoring
system to discriminate expected survival or recurrence outcomes
(data not shown).
We observed a significant correlation between nodal metastases
and DFS, and including this parameter into our scoring system
enhanced prognostication of both DSS and DFS (data not
shown). Lymph node ratio (defined as the ratio of positive lymph
nodes to the total number of lymph nodes examined) was also
prognostically relevant, but its inclusion did not improve the
prognostic strength of our scoring system over that seen with
nodal status alone (data not shown). In a study of 29 patients with
resected pancreatic neuroendocrine neoplasms, Sarmiento et al.
reported a statistically significant association between lymph node
metastases and OS.24 As stated above, the pancreatic adenocarci-
noma AJCC TNM staging system, which incorporates the pres-
ence of nodal metastases, has also been found to have some utility
for pancreatic neuroendocrine neoplasms.8,12,18 Previous analysis
has demonstrated that the presence of lymph node metastases
does not correlate with tumour size;4 this biological independence
may explain its utility as an independent variable in our proposed
SGNM scoring system.
We observed a strong association between positive resection
margins and worse DFS (P < 0.001), whereas the association
between positive resection margins and DSS neared but did not
reach statistical significance (P = 0.074). Few other studies have
examined the prognostic impact of this variable. In a study of 60
patients with resected pancreatic neuroendocrine neoplasms with
and without distant metastases, Phan et al. found margin status to
be the most powerful predictor of survival; the impact of margin
status on survival of patients without metastases was not
reported.2 In a recent study of patients undergoing partial hepa-
tectomy for hepatic neuroendocrine neoplasms,margin status was
also associated with survival.23
Our study is clearly limited by its relatively small sample size,
its reliance on a single-institution database, and the retrospective
nature of its data collection. As a result, our proposed SGNM
scoring system will require validation either prospectively or
with larger datasets. Perhaps as a result of the small number of
deaths in our series (despite its 68-month follow-up), the
scoring system appears to have more utility for the prediction of
recurrence than death. Importantly, the onset of disease recur-
rence portended an adverse outcome, as recurrence was associ-
ated with decreased survival (P = 0.012). Given the prolonged
survival that is to be expected in patients undergoing resection
of pancreatic neuroendocrine neoplasms, further discrimination
of differences in DSS will probably require a larger sample size
and longer follow-up. We did not examine the prognostic value
of tumour secretory function because the majority of previous
studies have not shown an association.4,14,26,27 Although some
authors have reported that functional tumours have better prog-
noses than non-functional neoplasms,26,28,29 this finding probably
reflects symptoms produced by hormone secretion, which lead
to earlier diagnosis and smaller tumour size at the time of
resection.2,4,24 Finally, we were unable to control for utilization of
postoperative oncological therapies in this retrospective
analysis. However, in light of the paucity of effective adjuvant
therapies available for patients with resected pancreatic neuroen-
docrine neoplasms,30 it is unlikely that the use of such
treatments would have significantly altered the course of
post-resection survival.
In conclusion, we propose a simple SGNM scoring system that
utilizes the reproducible and readily evaluable parameters of
tumour size 5 cm, histological grade, nodal metastases and
resection margin status to stratify patients who are undergoing
potentially curative resection of pancreatic neuroendocrine neo-
plasms according to their risk for recurrence and death.
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